SG10201408073XA - Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target - Google Patents
Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given targetInfo
- Publication number
- SG10201408073XA SG10201408073XA SG10201408073XA SG10201408073XA SG10201408073XA SG 10201408073X A SG10201408073X A SG 10201408073XA SG 10201408073X A SG10201408073X A SG 10201408073XA SG 10201408073X A SG10201408073X A SG 10201408073XA SG 10201408073X A SG10201408073X A SG 10201408073XA
- Authority
- SG
- Singapore
- Prior art keywords
- muteins
- hngal
- lcn2
- affinity
- given target
- Prior art date
Links
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 title abstract 3
- 102000047202 human LCN2 Human genes 0.000 title abstract 3
- 101150055061 LCN2 gene Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 102000016359 Fibronectins Human genes 0.000 abstract 1
- 108010067306 Fibronectins Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00041—Use of virus, viral particle or viral elements as a vector
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26709809P | 2009-12-07 | 2009-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201408073XA true SG10201408073XA (en) | 2015-01-29 |
Family
ID=43597993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201408073XA SG10201408073XA (en) | 2009-12-07 | 2010-12-07 | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
Country Status (12)
Country | Link |
---|---|
US (3) | US9549968B2 (ja) |
EP (3) | EP3660510A3 (ja) |
JP (4) | JP5913120B2 (ja) |
KR (2) | KR101842076B1 (ja) |
CN (1) | CN102770764B (ja) |
AU (1) | AU2010329995B2 (ja) |
BR (1) | BR112012013662B1 (ja) |
CA (1) | CA2779562C (ja) |
DK (2) | DK2990798T3 (ja) |
RU (2) | RU2564125C2 (ja) |
SG (1) | SG10201408073XA (ja) |
WO (1) | WO2011069992A2 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3660510A3 (en) * | 2009-12-07 | 2020-07-08 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
WO2012022742A1 (en) * | 2010-08-16 | 2012-02-23 | Pieris Ag | Binding proteins for hepcidin |
US9758554B2 (en) | 2012-01-31 | 2017-09-12 | Technische Universitaet Muenchen | Muteins of α1m lipocalin and method of production therefor |
WO2013174783A1 (en) * | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
EP3441400B1 (en) | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
BR112016027024A2 (pt) | 2014-05-22 | 2017-10-31 | Pieris Pharmaceuticals Gmbh | polipeptídeos de ligação específica e seus usos |
US10526382B2 (en) * | 2015-01-28 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof |
EP3064507A1 (en) | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
AU2016258977C1 (en) | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
US11261221B2 (en) | 2015-05-04 | 2022-03-01 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
CN107787327B (zh) | 2015-05-18 | 2022-02-08 | 皮里斯制药有限公司 | 对磷脂酰肌醇聚糖-3(gpc3)具有亲和力的人脂质运载蛋白2的突变蛋白 |
CN108112253B (zh) | 2015-05-18 | 2022-09-23 | 皮里斯制药有限公司 | 抗癌融合多肽 |
EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
BR112018010887A2 (pt) * | 2015-11-30 | 2018-11-21 | Pieris Australia Pty Ltd | polipeptídeo de fusão |
TW201725212A (zh) * | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
WO2018015380A1 (en) | 2016-07-18 | 2018-01-25 | Philippe Ulsemer | Natural microorganisms which are naturally capable of binding toxins and/or toxin receptors |
GB201615254D0 (en) | 2016-09-08 | 2016-11-23 | Ge Healthcare Bio Sciences Ab | Novel Ligand and use thereof |
CN107403074B (zh) * | 2017-06-09 | 2018-05-29 | 天津市湖滨盘古基因科学发展有限公司 | 一种突变蛋白的检测方法及装置 |
EP3715370A1 (en) * | 2019-03-28 | 2020-09-30 | Technische Universität München | High affinity anticalins directed against human cd98hc |
EP3946417A1 (en) | 2019-03-29 | 2022-02-09 | Pieris Pharmaceuticals GmbH | Inhaled administration of lipocalin muteins |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
EP0257956B2 (en) | 1986-08-19 | 2000-11-22 | Genentech, Inc. | Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion |
JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法 |
FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
AU696387B2 (en) | 1994-05-18 | 1998-09-10 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
WO1998016873A1 (fr) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Procede de preparation de dispersions a base de composants chromogenes |
US6020163A (en) | 1997-08-06 | 2000-02-01 | Zymogenetics, Inc. | Lipocalin homolog |
US20140080177A1 (en) | 1997-09-26 | 2014-03-20 | Pieris Ag | Anticalins |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
TR200003635T2 (tr) | 1998-06-08 | 2001-04-20 | F.Hoffmann-La Roche Ag | Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması. |
US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
CA2343917A1 (en) | 1998-10-19 | 2000-04-27 | Ariad Gene Therapeutics, Inc. | Materials and methods involving conditional retention domains |
ES2290023T3 (es) * | 1999-03-04 | 2008-02-16 | Praecis Pharmaceuticals Incorporated | Moduladores de la agregacion del peptido beta-amiloide que comprenden d-aminoacidos. |
DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
JP2007284351A (ja) * | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
EP1929073A4 (en) | 2005-09-27 | 2010-03-10 | Amunix Inc | PROTEIN MEDICAMENT AND ITS USE |
CA2659413C (en) * | 2006-08-01 | 2016-06-14 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
CN101516907B (zh) * | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
JP2011501673A (ja) * | 2007-10-19 | 2011-01-13 | アボット・ラボラトリーズ | グリコシル化された哺乳動物ngal及びその使用 |
AU2009264214B2 (en) | 2008-06-24 | 2013-06-06 | Technische Universitaet Muenchen | Muteins of hNGAL and related proteins with affinity for a given target |
EP3660510A3 (en) * | 2009-12-07 | 2020-07-08 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
WO2012022742A1 (en) * | 2010-08-16 | 2012-02-23 | Pieris Ag | Binding proteins for hepcidin |
JP6100694B2 (ja) | 2010-11-15 | 2017-03-22 | ピエリス ファーマシューティカルズ ゲーエムベーハー | グリピカン−3(gpc3)に対して親和性を有するヒトリポカリン2の突然変異タンパク質 |
EP3441400B1 (en) * | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
US10526382B2 (en) * | 2015-01-28 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof |
AU2016221816B2 (en) | 2015-02-18 | 2020-07-02 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for pyoverdine and pyochelin |
US11261221B2 (en) | 2015-05-04 | 2022-03-01 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
CN107787327B (zh) | 2015-05-18 | 2022-02-08 | 皮里斯制药有限公司 | 对磷脂酰肌醇聚糖-3(gpc3)具有亲和力的人脂质运载蛋白2的突变蛋白 |
TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2010
- 2010-12-07 EP EP19198835.1A patent/EP3660510A3/en active Pending
- 2010-12-07 KR KR1020127017730A patent/KR101842076B1/ko active IP Right Grant
- 2010-12-07 WO PCT/EP2010/069028 patent/WO2011069992A2/en active Application Filing
- 2010-12-07 DK DK15186647T patent/DK2990798T3/da active
- 2010-12-07 BR BR112012013662-3A patent/BR112012013662B1/pt active IP Right Grant
- 2010-12-07 EP EP15186647.2A patent/EP2990798B1/en active Active
- 2010-12-07 AU AU2010329995A patent/AU2010329995B2/en active Active
- 2010-12-07 KR KR1020187007781A patent/KR101974044B1/ko active IP Right Grant
- 2010-12-07 SG SG10201408073XA patent/SG10201408073XA/en unknown
- 2010-12-07 RU RU2012128586/10A patent/RU2564125C2/ru active
- 2010-12-07 DK DK10784824.4T patent/DK2510357T3/en active
- 2010-12-07 JP JP2012542505A patent/JP5913120B2/ja active Active
- 2010-12-07 EP EP10784824.4A patent/EP2510357B1/en active Active
- 2010-12-07 CN CN201080055370.5A patent/CN102770764B/zh active Active
- 2010-12-07 US US13/514,133 patent/US9549968B2/en active Active
- 2010-12-07 CA CA2779562A patent/CA2779562C/en active Active
- 2010-12-07 RU RU2015137158A patent/RU2707126C2/ru active
-
2015
- 2015-12-02 JP JP2015236010A patent/JP6346159B2/ja active Active
-
2016
- 2016-12-15 US US15/380,168 patent/US10618941B2/en active Active
-
2018
- 2018-05-24 JP JP2018099240A patent/JP2018148914A/ja active Pending
-
2020
- 2020-03-06 US US16/812,069 patent/US11827681B2/en active Active
- 2020-07-07 JP JP2020117175A patent/JP2021006024A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201408073XA (en) | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target | |
WO2007067730A3 (en) | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use | |
SG170080A1 (en) | Human monoclonal antibodies to o8e | |
MX2010004915A (es) | Anticuerpos para gdf8 asi como sus usos. | |
WO2007067992A3 (en) | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 | |
EA201270758A1 (ru) | Мутанты fgf21 и их применение | |
EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
UA97473C2 (ru) | Выделенное антитело, которое связывается с her-3, и его применение | |
MX2010000537A (es) | Anticuerpos monoclonales contra glipicano-3. | |
MX2009002816A (es) | Proteinas de fusion de albumina. | |
SG163554A1 (en) | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) | |
TNSN08064A1 (en) | Albumin fusion proteins | |
UA113609C2 (xx) | Антигензв'язуючий білок, який зв'язує людський il-23 | |
MX2010008570A (es) | Anticuerpos alfa5-beta1 y sus usos. | |
MY177065A (en) | 4-1bb binding molecules | |
EA201270713A1 (ru) | Белки на основе фибронектина с каркасными доменами, которые связывают ил-23 | |
WO2006089230A3 (en) | Human monoclonal antibodies to prostate specific membrane antigen (psma) | |
EA201990619A1 (ru) | Fgf21 мутанты и их применение | |
MX2009002418A (es) | Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso. | |
EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
MX2008009886A (es) | Anticuerpos que enlazan par-2. | |
UA97516C2 (ru) | Полностью человеческое моноклональное антитело против vap-1 | |
EA201290849A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
BR112012018914A2 (pt) | "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica." | |
JO3188B1 (ar) | بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل |